Autres langues UCB

Actions

Marché Fermé - Euronext Bruxelles 17:55:00 12/08/2026			Pré-ouverture 08:00:20
221,80 ^EUR	-1,95%		222,60	+0,36%

11/08	Berenberg ajuste ses prévisions pour UCB après des résultats semestriels supérieurs aux attentes ; recommandation d'achat confirmée	MT
11/08	UCB bouge peu malgré les avis positifs d'ING et Berenberg

11/08	Berenberg Adjusts UCB Forecasts After H1 Beat; Buy Reaffirmed
11/08	Berenberg herhaalt koopadvies UCB
10/08	MoonLake's psoriatic arthritis drug meets key goals in late-stage trial
05/08	UCB Publishes Results Of Post Hoc Data Analysis Of Fintepla In Patients With Lennox-Gastaut Syndrome
03/08	Barclays verlaagt koersdoel UCB
03/08	Jefferies haalt UCB van de verkooplijst
02/08	Umicore en Syensqo blinken uit na cijfers
30/07	UCB SA Reports Earnings Results for the Half Year Ended June 30, 2026
30/07	Nieuwe outlook UCB schiet tekort
30/07	Goede eerste jaarhelft voor UCB
30/07	Goede eerste jaarhelft voor UCB
30/07	UCB shares fall despite guidance upgrade as CEO flags higher H2 costs
30/07	UCB : Delivering today, shaping what comes next
30/07	UCB verhoogt verwachting na sterk halfjaar
30/07	Biopharmaceutical Company UCB Books Higher H1 Profit, Revenue
30/07	UCB raises guidance for core earnings and revenue
30/07	UCB : Delivers Strong Results, Raises 2026 Guidance and Positions for Next Growth Phase
29/07	Omzetgroei bij UCB verwacht
24/07	Bedrijfskalender van 27 tot 31 juli 2026
24/07	Calendario delle società: 27 - 31 luglio 2026
14/07	Where would AI lead Pharma in the long run?
13/07	Antengene Receives $60 Million Milestone in UCB Licensing Deal
12/07	Melexis onderuit in Brussel te midden van AI-malaise
09/07	UK Life Sciences Hits GBP3 Billion Investment Milestone
08/07	UCB presenteert nieuwe studiedata